Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.
Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become...